Interactions between outcomes and tumor response to preoperative cisplatin-sensitized radiotherapy in advanced head and neck cancer - 11/09/11

Doi : 10.1016/S0002-9610(97)00151-7

Martin D. Goodman, MD, Michael Tarnoff, MD, Michael Kain, BA, Gus J. Slotman, MD ^⁎
Southern New Jersey Head and Neck Cancer Treatment Group^{^⋆}
The Southern New Jersey Head and Neck Cancer Treatment Group includes: Jorge Cassir, MD, Jeffrey Meltzer, MD, James Dalzell, MD, Naim Nazha, MD, David Sykes, DMD, Atlantic City; Julianna Childs, DO, Marmora; Albert Poet, MD, Victor Ruiz, MD, Manahawkin; Carolyn Horowitz, MD, Alexis Harvey, MD, Harvey Rothman, DO, Marlton; Joseph Fanelle, MD, William Robertello, MD, Woodbury; Arthur Ferrari, MD, David Blom, MD, Rama Sudhindra, MD, Vineland; Edward Noble, DMD, Bradford Porter, DMD, Kenneth Goldberg, DMD, Haddonfield; Robert Lustig, MD, Alex Hageboutros, MD, Camden; Joseph Matise, DMD, Medford.
From the Department of Surgery, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, Cooper Hospital/University Medical Center, Camden, New Jersey, USA

^*Requests for reprints should be addressed to Gus J. Slotman, MD, Department of Surgery, Cooper Hospital, 3 Cooper Plaza, Suite 411, Camden, New Jersey 08103.

Abstract

background

Whether or not tumor response to chemotherapy-sensitized radiation therapy (CTRT) for head and neck cancer leads to an improved outcome is unknown.

methods

Forty patients who received preoperative cisplatin plus simultaneous radiotherapy for operable stage III and IV head and neck cancer were reviewed retrospectively regarding clinical demographics, staging, and survival status.

results

Twenty-one (57%) patients had a histologic complete response (HCR) and 16 (43%) had a partial (PR) (9) or clinical complete (7) response (CCR). Tumor response of N₁ versus N_2–3 nodal disease showed 6 (75%) HCR and 4 (25%). Fiveyear disease-free survival overall was 82% for HCR versus 38% for PR/CCR (P < 0.05). Disease specific 5-year survival was 100% for HCR versus 27% for PR/CCR (P <0.002).

conclusions

Histologic complete response to CTRT for head and neck cancer is associated with increased survival and encouraging disease free status. Response to CTRT is inversely proportional to lymphatic tumor load.

Le texte complet de cet article est disponible en PDF.

**	Presented at the 43rd Annual Meeting of The Society of Head and Neck Surgeons, Cancún, Mexico, April 10–12, 1997.

Export

Vol 174 - N° 5

P. 527-531 - novembre 1997 Retour au numéro

Article précédent

Tumor angiogenesis as a prognostic factor in laryngeal cancer
John D. Murray, Grant W. Carlson, Kevin McLaughlin, Marian Pennington, Michael Lynn M.S., Patricia B. DeRose, J. Kerwin Williams, Cynthia Cohen

| Article suivant

Recurrence patterns with concurrent platinum-based chemotherapy and accelerated hyperfractionated radiotherapy in stage iii and iv head and neck cancer patients
R. James Koness, Arvin Glicksman, Li Liu, Noreen Coachman, Christine Landman, Gus Slotman, Harold J. Wanebo

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Interactions between outcomes and tumor response to preoperative cisplatin-sensitized radiotherapy in advanced head and neck cancer - 11/09/11

Abstract

background

methods

results

conclusions

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL